- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Resistance to targeted therapies: delving into FLT3 and IDH ; volume:12 ; number:6 ; day:9 ; month:6 ; year:2022 ; pages:1-8 ; date:6.2022
Blood cancer journal ; 12, Heft 6 (9.6.2022), 1-8, 6.2022
- Creator
-
Desikan, Sai Prasad
Daver, Naval
DiNardo, Courtney
Kadia, Tapan
Konopleva, Marina
Ravandi, Farhad
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-022-00687-5
- URN
-
urn:nbn:de:101:1-2022080608004830218254
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Desikan, Sai Prasad
- Daver, Naval
- DiNardo, Courtney
- Kadia, Tapan
- Konopleva, Marina
- Ravandi, Farhad
- SpringerLink (Online service)
Other Objects (12)
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
IDH
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
IDH
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML